AMPH - CIK 0001297184
The table below shows Amphastar Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $170.94M | $216.26M | $187.69M | $182.78M | $192.12M | $189.62M |
| Short-term investments | $121.01M | $59.94M | $44.06M | $54.10M | $58.38M | $28.16M |
| Receivables | $147.85M | $146.81M | $132.98M | $144.64M | $139.63M | $131.41M |
| Inventory | $170.19M | $185.93M | $191.73M | $185.48M | $130.32M | $122.41M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $633.68M |
| $639.47M |
| $580.83M |
| $587.96M |
| $545.95M |
| $482.64M |
| Property, plant & equipment | $307.23M | $308.69M | $310.24M | $307.60M | $295.38M | $288.00M |
| Goodwill | $3.33M | $3.40M | $3.40M | $3.16M | $3.26M | $3.13M |
| Total assets | $1.65B | $1.67B | $1.62B | $1.63B | $1.55B | $1.49B |
| Accounts payable | $35.50M | $40.54M | $41.88M | $52.81M | $34.09M | $31.77M |
| Total current liabilities | $164.48M | $205.23M | $176.41M | $199.05M | $159.01M | $136.97M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $874.77M | $889.48M | $857.85M | $874.99M | $817.50M | $778.18M |
| Retained earnings | $673.30M | $642.45M | $625.10M | $594.07M | $530.82M | $490.39M |
| Total equity | - | - | - | - | - | - |